1. Volume 147, Issue 2, Pages 484-494 (February 2015)
Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study 
Robert P. Frantz, MD, Robert J. Schilz, DO, PhD, FCCP, Murali M. Chakinala, MD, FCCP, David B. Badesch, MD, FCCP, Adaani E. Frost, MD, FCCP, Vallerie V. McLaughlin, MD, FCCP, Robyn J. Barst, MD, Daniel M. Rosenberg, PhD, Dave P. Miller, MS, Brian K. Hartline, MD, Wade W. Benton, PharmD, Harrison W. Farber, MD, FCCP 
CHEST 
Volume 147, Issue 2, Pages (February 2015)
DOI: /chest
Copyright © 2015 The American College of Chest Physicians Terms and Conditions

2. Figure 1
Rates of on-study hospitalizations* (per 1, 000 patient-d) in the PROSPECT cohort by prostacyclin history. *On-study hospitalization defined as those with a date of hospital admission after the date of enrollment into PROSPECT.
CHEST  , DOI: ( /chest )
Copyright © 2015 The American College of Chest Physicians Terms and Conditions

3. Figure 2
A, B, Freedom from hospitalization at 1 y by prostacyclin history (A) and sex (B).
CHEST  , DOI: ( /chest )
Copyright © 2015 The American College of Chest Physicians Terms and Conditions

4. Figure 2
A, B, Freedom from hospitalization at 1 y by prostacyclin history (A) and sex (B).
CHEST  , DOI: ( /chest )
Copyright © 2015 The American College of Chest Physicians Terms and Conditions

5. Figure 3 A, B, One-y survival by prostacyclin history (A) and sex (B).
CHEST  , DOI: ( /chest )
Copyright © 2015 The American College of Chest Physicians Terms and Conditions

6. Figure 3 A, B, One-y survival by prostacyclin history (A) and sex (B).
CHEST  , DOI: ( /chest )
Copyright © 2015 The American College of Chest Physicians Terms and Conditions